EP2755685A4 - TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES - Google Patents
TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASESInfo
- Publication number
- EP2755685A4 EP2755685A4 EP11872271.9A EP11872271A EP2755685A4 EP 2755685 A4 EP2755685 A4 EP 2755685A4 EP 11872271 A EP11872271 A EP 11872271A EP 2755685 A4 EP2755685 A4 EP 2755685A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- toll
- antagonists
- metabolic
- receptor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/051202 WO2013039471A1 (en) | 2011-09-12 | 2011-09-12 | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2755685A1 EP2755685A1 (en) | 2014-07-23 |
EP2755685A4 true EP2755685A4 (en) | 2015-07-01 |
Family
ID=47883555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11872271.9A Ceased EP2755685A4 (en) | 2011-09-12 | 2011-09-12 | TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2755685A4 (ja) |
JP (1) | JP2014526464A (ja) |
KR (1) | KR20140075708A (ja) |
CN (1) | CN104159610A (ja) |
BR (1) | BR112014005786A2 (ja) |
CA (1) | CA2855955A1 (ja) |
EA (1) | EA201490623A1 (ja) |
IL (1) | IL231413A0 (ja) |
MX (1) | MX362457B (ja) |
NZ (1) | NZ622260A (ja) |
WO (1) | WO2013039471A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014174704A1 (ja) * | 2013-04-22 | 2014-10-30 | 国立大学法人東京大学 | 炎症性疾患の予防又は治療剤 |
WO2015016282A1 (ja) * | 2013-07-30 | 2015-02-05 | 国立大学法人東京大学 | 放射線誘導性消化管症候群の予防又は治療用医薬組成物 |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
IL258317B1 (en) | 2015-10-02 | 2024-08-01 | Hoffmann La Roche | Human anti–CD20/human transferrin receptor bispecific antibodies and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010051470A2 (en) * | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Toll-like receptor 3 antagonists |
WO2010127113A2 (en) * | 2009-04-29 | 2010-11-04 | Centocor Ortho Biotech Inc. | Toll-like receptor 3 antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
AR051836A1 (es) * | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
CN101415438B (zh) * | 2004-11-30 | 2013-03-27 | 森托科尔公司 | Toll样受体3拮抗剂、方法和用途 |
EP2155889A4 (en) * | 2007-05-25 | 2010-06-16 | Centocor Ortho Biotech Inc | TOLL RECEPTOR 3 MODULATORS AND USES THEREOF |
EP2344175B1 (en) * | 2008-10-02 | 2015-07-22 | Janssen Biotech, Inc. | Methods for suppressing toll-like receptor activity |
EP2347038A4 (en) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES |
-
2011
- 2011-09-12 WO PCT/US2011/051202 patent/WO2013039471A1/en active Application Filing
- 2011-09-12 CA CA2855955A patent/CA2855955A1/en not_active Abandoned
- 2011-09-12 JP JP2014529662A patent/JP2014526464A/ja active Pending
- 2011-09-12 BR BR112014005786A patent/BR112014005786A2/pt not_active Application Discontinuation
- 2011-09-12 EP EP11872271.9A patent/EP2755685A4/en not_active Ceased
- 2011-09-12 EA EA201490623A patent/EA201490623A1/ru unknown
- 2011-09-12 CN CN201180074797.4A patent/CN104159610A/zh active Pending
- 2011-09-12 NZ NZ622260A patent/NZ622260A/en not_active IP Right Cessation
- 2011-09-12 MX MX2014002982A patent/MX362457B/es active IP Right Grant
- 2011-09-12 KR KR1020147009316A patent/KR20140075708A/ko not_active Application Discontinuation
-
2014
- 2014-03-09 IL IL231413A patent/IL231413A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010051470A2 (en) * | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Toll-like receptor 3 antagonists |
US20100166778A1 (en) * | 2008-10-31 | 2010-07-01 | Mark Cunningham | Toll-Like Receptor 3 Antagonists |
WO2010127113A2 (en) * | 2009-04-29 | 2010-11-04 | Centocor Ortho Biotech Inc. | Toll-like receptor 3 antagonists |
Non-Patent Citations (1)
Title |
---|
See also references of WO2013039471A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN104159610A (zh) | 2014-11-19 |
CA2855955A1 (en) | 2013-03-21 |
NZ622260A (en) | 2016-11-25 |
WO2013039471A1 (en) | 2013-03-21 |
KR20140075708A (ko) | 2014-06-19 |
EP2755685A1 (en) | 2014-07-23 |
MX2014002982A (es) | 2015-07-06 |
BR112014005786A2 (pt) | 2017-03-28 |
MX362457B (es) | 2019-01-18 |
JP2014526464A (ja) | 2014-10-06 |
IL231413A0 (en) | 2014-04-30 |
EA201490623A1 (ru) | 2016-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257581A (en) | New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders | |
EP2900266A4 (en) | TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES | |
EP2773263A4 (en) | METABOLIC AND CARDIO-PULMONARY MONITORING DEVICE | |
ZA201308421B (en) | Compositions uses and methods for treatment of metabolic disorders and diseases | |
EP2739144A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
PL2593095T3 (pl) | (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania | |
HK1201454A1 (en) | Therapeutic agents and uses thereof | |
IL223286A0 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
ME02180B (me) | Supstanca korisna za lečenje poremećaja metabolizma lipida | |
ZA201304822B (en) | Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases | |
IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
EP2755685A4 (en) | TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES | |
EP2841077A4 (en) | NUTRITIONAL FIBER COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISORDERS | |
GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
IL234616A0 (en) | A herbal preparation for the treatment of metabolic diseases | |
HK1182712A1 (en) | Therapeutic agents 976 976 | |
GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
EP2600716A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES | |
GB201019482D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201006164D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201006163D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201004740D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201004744D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201004742D0 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140411 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150603 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101AFI20150528BHEP Ipc: C07K 16/28 20060101ALI20150528BHEP |
|
17Q | First examination report despatched |
Effective date: 20170512 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20191226 |